Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing by 源��꽦�젹 et al.
231https://e-aair.org
ABSTRACT
Purpose: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing 
muscle spasm and pain. For more effective pain control, eperisone is usually prescribed 
together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may 
have been overlooked as the cause of anaphylaxis compared with NSAIDs. This study aimed 
to analyze the adverse drug reaction (ADR) reported in Korea and suggest an appropriate 
diagnostic approach for eperisone-induced anaphylaxis.
Methods: We reviewed eperisone-related pharmacovigilance data (Korea Institute of Drug 
Safety-Korea Adverse Event Reporting System [KIDS-KAERS]) reported in Korea from 2010 
to 2015. ADRs with causal relationship were selected. Clinical manifestations, severity, 
outcomes, and re-exposure information were analyzed. For further investigation, 7-year ADR 
data reported in a single center were also reviewed. Oral provocation test (OPT), skin prick 
test (SPT) and basophil activation test (BAT) were performed in this center.
Results: During the study period, 207 patients had adverse reactions to eperisone. The most 
common ADRs were cutaneous hypersensitive reactions (30.4%) such as urticaria, itchiness 
or angioedema. Fifth common reported ADR was anaphylaxis. There were 35 patients with 
anaphylaxis, comprising 16.9% of the eperisone-related ADRs. In the single center study, 
there were 11 patients with eperisone-induced anaphylaxis. All the patients underwent 
OPT and all the provoked patients showed a positive reaction. Four of the 11 patients with 
anaphylaxis also underwent SPT and BAT, which were all negative.
Conclusions: Incidence of eperisone-induced anaphylaxis calculated from the KIDS-KAERS 
database was 0.001%. Eperisone can cause hypersensitive reactions, including anaphylaxis, 
possibly by inducing non-immunoglobulin E-mediated immediate hypersensitivity.
Keywords: Adverse drug reaction; anaphylaxis; eperisone; hypersensitivity; 
non-steroidal anti-inflammatory agents
Allergy Asthma Immunol Res. 2019 Mar;11(2):231-240
https://doi.org/10.4168/aair.2019.11.2.231
pISSN 2092-7355·eISSN 2092-7363
Original Article
Received: Aug 6, 2018
Revised: Sep 10, 2018
Accepted: Sep 22, 2018
Correspondence to
Jung-Won Park, MD, PhD
Division of Allergy and Immunology, 
Department of Internal Medicine, Yonsei 
University College of Medicine, 50-1 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea. Tel: +82-
2-2228-1961; Fax: +82-2-393-6884;
E-mail: parkjw@yuhs.ac
Copyright © 2019 The Korean Academy of 
Asthma, Allergy and Clinical Immunology • 
The Korean Academy of Pediatric Allergy and 
Respiratory Disease
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
Disclosure
There are no financial or other issues that 
might lead to conflict of interest.
Kyung Hee Park,1,2 Sang Chul Lee,1,2 Ji Eun Yuk,2 Sung-Ryeol Kim,1,2  
Jae-Hyun Lee,1,2 Jung-Won Park1,2*
1 Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of 
Medicine, Seoul, Korea
2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Eperisone-Induced Anaphylaxis: 
Pharmacovigilance Data and Results 
of Allergy Testing
INTRODUCTION
Eperisone hydrochloride (4′-ethyl-2-methyl-3-piperidinopropiophenone hydrochloride) is a 
centrally acting oral muscle relaxant used for painful muscle spasm and spasticity associated 
with musculoskeletal disorders. It directly acts on the motor nerve to hyperpolarize the 
action potential, resulting in reduction of nerve conduction and sensitivity of the muscle 
spindle contraction.1 Eperisone yields not only muscle relaxation, but also analgesic effects by 
inhibiting the release of substance P.2 In addition, it has a vasodilator effect through a calcium 
antagonist and sympatho-suppressive action that leads to improved muscular blood flow.3,4
In previous double-blind randomized studies using eperisone, only gastrointestinal 
symptoms were reported as adverse reactions, and no allergic reactions were reported.3,5,6 In a 
recent systematic literature review paper, neither hypersensitive reaction nor anaphylaxis was 
reported after use of eperisone.7
For effective pain control, nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, and 
centrally acting muscle relaxants such as eperisone are prescribed concomitantly.6 NSAIDs 
are well-known to induced adverse drug reactions (ADRs) and are considered a culprit 
drug ahead of others when hypersensitivity reaction occurs with multiple drugs. Therefore, 
centrally acting muscle relaxants have been overlooked as a cause of ADR. In this study, we 
analyzed the incidence, clinical manifestations and immunologic mechanisms of eperisone-
induced ADRs, particularly anaphylaxis.
MATERIALS AND METHODS
Subjects
Pharmacovigilance data of eperisone were collected from the Korea Institute of Drug Safety-
Korea Adverse Event Reporting System (KIDS-KAERS) database of the Korea Institute 
of Drug Safety and Risk Management (Ministry of Food and Drug Safety). Data on ADRs 
nationwide reported by doctors, nurses, pharmacists, pharmaceutical employers and 
patients are all collected in this system.8 The KIDS-KAERS database provides information 
on age, sex, reporting personnel, generic name of the drug, administration day/dose/route, 
clinical manifestations/severity, re-challenge and causality criteria. It uses the Anatomical 
Therapeutic Chemical Classification System for drug name, World Health Organization 
(WHO)-Adverse Reaction Terminology for clinical manifestations and World Health 
Organization-Uppsala Monitoring Center (WHO-UMC) causality criteria for assessment.9 
ADR reports from January 2010 to December 2015 were analyzed. From this database, cases 
in which eperisone was reported only as a suspected drug and not as concomitant medication 
were used for the analysis. Cases in which causal relationship was assessed as certain or 
probable/likely were selected.
For a more accurate analysis of hypersensitivity, all reports were reviewed and revalidated 
if they were indeed anaphylaxis according to the WHO diagnostic criteria.10 Reviews were 
doctors who certified with a subspecialty in allergy. They had a minimum of 7 years of 
experience in the pharmacovigilance field. To overcome the limited medical information 
of anonymously converted computerized database, Severance Hospital (Seoul, Korea) 
pharmacovigilance data from January 2010 to December 2017 were analyzed for a more 
detailed investigation. This tertiary teaching hospital in Yonsei University operates a 
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well-established pharmacovigilance system, and drug allergy tests (e.g., skin test, patch 
test, serum-specific immunoglobulin E (IgE) test, tryptase, provocation test and basophil 
activation test [BAT]) are available. Past medical history, drug history and underlying 
conditions for the use of eperisone were thoroughly reviewed. The study design schematic 
is shown in Fig. 1. This study was approved by the Institutional Review Board of the Yonsei 
University Health System (No. 2018-0770-001).
Skin prick test (SPT)
Eperisone (Exoperin®; Hanmi Pharmaceutical, Seoul, Korea) dissolved in normal saline 
to a concentration of 10 mg/mL was used for SPT. Normal saline with 0.3% phenol and 
50% glycerol was used as the negative control, and 0.1% histamine (Allergy Therapeutics, 
Worthing, UK) was used as the positive control. All participants discontinued medications 
that might influence the test result. Wheal and erythema sizes were measured after 15 
minutes, and wheal sizes greater than 3 mm were considered positive reactions. As eperisone 
is only available in oral tablet form in Korea, intradermal test was not performed in this study 
considering the patients' safety.
Oral provocation test (OPT) and tryptase
Patients requiring oral challenge were admitted to the hospital for close monitoring of 
adverse reactions. Open challenge OPT was performed using medications suspected to 
induce anaphylaxis. Eperisone provocation test was started with 5 mg (1/10 of once dose) or 
10 mg (1/5 of once dose) according to previous anaphylactic reactions, increased to 10, 25 and 
50 mg per hour. OPT was conducted under the supervision of an allergy specialist, and the 
test was stopped immediately if an allergic reaction occurred. The tryptase level was checked 
using fluoroenzymeimmunoassay kits (Thermo Fisher Scientific Inc., Waltham, MA, USA) in 
cases of anaphylaxis.
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Fig. 1. Study design schematic. 
KIDS-KAERS, Korea Institute of Drug Safety-Korea Adverse Event Reporting System; ADR, adverse drug reaction.
BAT
Fresh whole blood from patients allergic to eperisone was collected in EDTA vacutainer 
tubes (BD Biosciences, San José, CA, USA), and BAT was performed with the FlowCAST® kit 
(BÜHLMANN, Schönenbuch, Switzerland) according to the manufacturer's protocol. Briefly, 
50 μL of the patient's whole blood was treated with various concentrations of eperisone (1, 
0.1, 0.01 and 0.001 mg/mL),11 positive controls (FcεRI Ab, fMLP), and background control in 
100 μL of stimulation buffer and staining reagent for 15 minutes at 37°C. For the cellular lysis, 
2 mL of lysing reagent was incubated for 15 minutes at 37°C. Then, samples were centrifuged, 
the supernatant was decanted, and the cell pellet was resuspended with 300 μL of wash 
buffer. Flow cytometric analysis was performed via FACS Verse (BD Biosciences). Data were 
analyzed using FlowJo software (TreeStar, Ashland, OR, USA). Stimulation index (SI) was 
calculated as follows:
SI = % of basophil activated by the drug/% of activated basophils in the negative control
If SI was 2 or more and activated basophils were increased by more than 5%, the basophil test 
was regarded as positive.
RESULTS
Characteristics of eperisone-induced anaphylaxis from the KIDS-KAERS 
database
There were 2,213 patients who had eperisone-induced ADRs. Among them, 207 whose ADRs 
were considered to have causal relationships (certain or probable/likely relationship based 
on the WHO-UMC criteria) were selected for analysis (Supplementary Table S1). The most 
common ADRs were cutaneous hypersensitive reactions (30.4%) such as urticaria, itchiness 
and angioedema. Anaphylaxis, a systemic hypersensitive reaction, developed in 16.9% of the 
patients (n = 35, Supplementary Table S2).
Information about the patients with eperisone anaphylaxis is shown in Table 1. The mean age 
was 50.6 years, and majority was women. Doctors reported the most number of anaphylaxis 
cases (48.6%) than other medical personnel. A total of 70% of enrolled cases were rated as 
“certain” in the causal relationship evaluation. Re-challenge information was available in 20 
patients, and 70% of them re-experienced ADRs.
Among the 35 patients with anaphylaxis, 26 (74.3%) were originally reported to have 
anaphylaxis and 9 were newly re-assessed to have anaphylaxis based on the WHO criteria. 
Respiratory (e.g., dyspnea and wheezing) and cardiovascular compromises were observed in 
45.7% and 20% of the patients, respectively. Meanwhile, 2.7% of the patients experienced 
altered mental status.
Clinical characteristics and allergy tests of patients with eperisone-induced 
anaphylaxis from a single center
The baseline characteristics of patients with eperisone-induced ADR at a single 
pharmacovigilance center are shown in Supplementary Table S3 (n = 37). The mean age 
was 56.5 years, and majority was women (64.9%). In this center, cutaneous manifestations 
(29.7%) and anaphylaxis (29.7%) were the most common ADRs. There were 11 patients 
who experienced eperisone-induced anaphylaxis. The demographics, co-administered 
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medications and results of the allergy diagnostic study are shown in Table 2. The average 
age was 53.9 years, and women were 2.7 times more likely to develop ADRs than men. Most 
patients were prescribed with eperisone due to muscle cramping (63.6%), and there were no 
patients who had any other allergic diseases. Eperisone was co-administered with NSAIDs, 
tramadol, acetaminophen or gastrointestinal protective agents.
Allergy screening test to determine the cause was performed using SPT, BAT and open 
challenge test. All the patients with anaphylaxis showed a positive reaction to OPT using 
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Table 1. Characteristics of eperisone-induced anaphylactic patients in the KIDS-KAERS database (n = 35)
Characteristic Value
Age (year) 50.6 ± 11.5
Sex (M:F) 15:20
Reporting personnel (n = 31)
Doctors 17 (48.6)
Nurses 3 (8.6)
Pharmacists 8 (22.9)
Patients 1 (2.9)
Unknown 2 (5.7)
Route of ranitidine administration (n = 35)
Oral 35 (100)
Intravenous NA
WHO-UMC* causality assessment (n = 35)
Certain 24 (68.6)
Probable/likely 11 (31.4)
Re-challenge information available (n = 20)
Re-challenge results reproduced 14 (70.0)
No information 6 (30.0)
Reported clinical manifestations (reports among 35 patients)
Anaphylaxis* 26 (74.3)
Cutaneous 16 (45.7)
Respiratory 16 (45.7)
Shock 7 (20.0)
Gastrointestinal 5 (14.3)
Mental status change 2 (2.7)
Casualty 0 (0)
Values are presented as mean ± standard deviation or number (%).
KIDS-KAERS, Korea Institute of Drug Safety-Korea Adverse Event Reporting System; M, male; F, female; WHO-
UMC, World Health Organization-Uppsala Monitoring Center; NA, not available.
*Among 35 patients with anaphylaxis, 26 were originally reported as anaphylactic.
Table 2. Characteristics and allergy test results eperisone anaphylactic patients in a single pharmacovigilance center (n = 11)
No. Age/sex Initial co-administered drugs 
with eperisone
SPT BAT Tryptase OPT Dose* 
(mg)
Time† 
(min)
Symptom and signs of OPT
1 60/F Aceclofenac, others‡ ND ND 8.53 Pos 25 55 Shock, generalized pruritis, chest discomfort
2 64/F Loxoprofen, others‡ ND ND ND Pos 50 60 Dyspnea, urticaria
3 51/M Aceclofenac, tramadol ND ND ND Pos 50 60 Shock, urticaria, angioedema
4 45/M Others‡ ND ND ND Pos 5 30 Dyspnea, urticaria, angioedema
5 56/F Acetaminophen, tramadol, others‡ ND ND 3.23 Pos 25 60 Generalized urticaria
6 32/M Aceclofenac, others‡ Neg Neg 15.5 Pos 5 15 Shock, angioedema, chest discomfort, dysphagia
7 70/F Loxoprofen Neg Neg ND Pos 5 10 Urticaria, dyspnea, chest discomfort, angioedema
8 50/F Aceclofenac, others‡ ND ND ND Pos 15 30 Shock, desaturation, urticaria
9 62/F Loxoprofen, others‡ ND ND ND Pos 15 210 Generalized rash
10 59/F Loxoprofen, acetaminophen, 
tramadol, others‡
Neg Neg ND Pos 5 30 Dyspnea, urticaria, angioedema, chest discomfort
11 59/F Aceclofenac, others‡ Neg Neg ND Pos 15 90 Shock, angioedema, dyspnea
M, male; F, female; SPT, skin prick test; BAT, basophil activation test; OPT, oral provocation test; ND, not done; Neg, negative reaction; Pos, positive reaction.
*Cumulative dose for positive reaction during OPT; †Onset time of positive reaction during OPT; ‡Others are gastrointestinal protective drugs such as rebamipide, 
almagate, or ranitidine.
eperisone. SPT of eperisone was performed in 4 patients, and all results were negative. 
BAT data of the 4 patients are shown in Supplementary Fig. S1A. None of the patients met 
the BAT positivity criteria described earlier. Tryptase levels were checked in 3 patients after 
anaphylaxis developed. One had elevated absolute levels (15.5 μg/L, reference range: 0-13.5 
μg/L), the other had a 7.7-fold elevation baseline tryptase (from 1.11 to 8.53 μg/L, measured 
after provocation test), while the other had no changes in tryptase levels. During OPT, 5 
patients experienced hypotension, and 7 patients showed urticaria and/or angioedema 
(Supplementary Fig. S1B). Cumulative dose for positive reaction was 5 to 50 mg of eperisone. 
On average, 59 minutes were taken for a positive reaction.
As other pain controllers such as NSAIDs are co-administered with eperisone, and they are 
more commonly known as the cause of drug allergy than eperisone, open challenge test using 
pain controllers were performed initially. However, all OPTs were negative for pain controllers. 
Therefore, eperisone was suspected to be the cause of anaphylaxis and OPT was performed.
DISCUSSION
In this study, we analyzed the nationwide incidence of eperisone-induced anaphylaxis 
including overall ADRs for the first time. In addition, SPT, OPT and BAT12 were performed 
to determine the mechanism of anaphylaxis. Several case reports of eperisone-induced 
anaphylaxis and ADRs have been published to date. The signs and symptoms of anaphylaxis 
and results of the diagnostic tests are summarized in Table 3.
A previous case series reported the highest number of patients with eperisone anaphylaxis 
in the Korean population. Eperisone is not available as an over-the-counter drug in Korea. 
To calculate the annual rate of eperisone-induced anaphylaxis, we collected nationwide 
prescription data from 2010 to 2015. The prescription of eperisone has increased by 44% from 
2010 to 2015. In proportion to this increase, the number of reported ADRs also increased by 
564% (Fig. 2). In 2015, 901,255 patients were prescribed with eperisone, and 73 cases of ADR, 
were reported, among which 14 were anaphylactic (calculated incidence: 0.001%). This shows 
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Table 3. Previous studies on eperisone-induced ADRs including anaphylaxis
Age (year)/
sex
Clinical manifestations Provocation 
test
SPT IDT BAT Patch test Reference
64/F Anaphylaxis (urticaria, throat swelling, and loss of 
consciousness)
Pos Neg ND Neg ND Miki et al.11
70/F Anaphylaxis (urticaria and shock) Pos Neg 
(10 mg/mL)
Pos 
(10 mg/mL)
ND ND Kim et al.15
63/F Anaphylaxis (urticaria, dyspnea, dysphagia, and 
chest pain)
Pos ND ND ND ND Kang et al.1
58/M Anaphylaxis (urticaria, shock, and loss of 
consciousness)
Pos* ND ND ND ND Kang et al.1
58/M Anaphylaxis (urticaria, dyspnea, and facial edema) Pos ND ND ND ND Kang et al.1
54/F Anaphylaxis (urticaria, angioedema, dyspnea, 
shock, and dizziness)
ND Neg Neg ND ND Hur et al.16
62/F Anaphylaxis (dyspnea and angioedema) ND Neg Neg ND ND Hur et al.16
23/M Drug eruption Pos NA NA NA NA Ueno and Kawana.22
30/M Severe maculopapular rash ND ND ND ND ND Balaraddiyavar et al.23
42/F Fixed drug eruption Pos ND ND ND ND Choonhakarn24
69/F Acute generalized exanthematous pustulosis ND ND ND ND Pos Yamamoto et al.25
ADR, adverse drug reaction; M, male; F, female; SPT, skin prick test; IDT, intradermal test; BAT, basophil activation test; Neg, negative reaction; Pos, positive 
reaction; ND, not done; NA, not available (published in Japanese except abstract).
*Confirmed by history: 3 times re-challenge.
that aside form NSAIDs, eperisone should also be regarded as a cause of anaphylaxis in patients 
receiving musculoskeletal pain control medications. Eperisone is considered to cause ADRs 
independent of any other co-administered drugs. In drug interaction studies, there was no 
known pharmacokinetic interaction between eperisone and aceclofenac13 and pelubiprofen.14
The findings of this study suggest that eperisone-induced anaphylaxis occurs through a non-
IgE mechanism. SPT and BAT were negative in this study. In previous reports, SPT yielded 
negative reactions,11,15,16 and only 1 case of positive intradermal test reaction has been reported.15 
However, this study did not indicate a non-irritating concentration of intradermal test. BAT was 
performed only in one previous study, which also yielded negative reaction.11 Collectively, these 
results indicate that eperisone-induced anaphylaxis can only be diagnosed through OPT.
In addition to anaphylaxis, drug eruption, severe maculopapular rash, fixed drug eruptions 
and acute generalized exanthematous pustulosis have been reported as ADRs to eperisone 
(Table 3). Moreover, aside from hypersensitive reactions, there were also several case reports 
on toxic reactions after administration of high-dose eperisone. An 18-month-old child lost 
consciousness and had seizure, apnea and ventricular tachycardia after accidentally taking 
100 mg of eperisone hydrochloride, which is equal to at least 1,000 to 2,000 mg eperisone 
in adults.17 There were toxicity reports of QT prolongation,18 torsades de pointes induced by 
severe QT prolongation after eperisone overdose and suicide attempt after taking triazolam 
combined with eperisone.19
In a previous efficacy and safety study, 7 of the 100 patients who received 300 mg per/day of 
eperisone reported ADRs of light-headedness (n = 1), vertigo and/or loss of equilibrium (n = 3), 
mild somnolence (n = 2), and epigastric pain (n = 1).20 Patients who received eperisone showed 
similar or lesser ADRs compared with those who received other pain relievers in a dose-ranging 
study. Eperisone 300 mg/day was effective and well-tolerated (cumulative ADR incidence: 
11.1%) compared with the placebo (cumulative ADR incidence: 16.7%).3 In a comparison study 
between eperisone and thiocolchicoside, the number of subjects who reported ADRs (nausea, 
epigastric discomfort and vomiting) was lower in the eperisone-treated group (5%) than in 
the thiocolchicoside-treated group (21.3%).6 In another efficacy and safety study comparing 
eperisone and baclofen, the eperisone-treated group showed better tolerability (47.4% patients 
had ADR) than the baclofen-treated group (77.1% patients had ADR).2
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Fig. 2. Number of prescriptions for eperisone and ADRs during 6 years. 
ADR, adverse drug reaction.
There is no evidence to suggest a cross-reactivity between eperisone and any other drugs. 
However, eperisone is closely related to tolperisone hydrochloride (dimethyl-2,4′-piperidino-
3-propiophenone) as their chemical structures are quite similar. A study suggested that cross-
reactivity of eperisone with tolperisone can also cause anaphylaxis.21 Chemical structures of 
eperisone and related compounds are shown in Fig. 3.
In this study, there are some limitations. First, this study analyzed the self-reported ADRs 
from heterogeneous reported personnel retrospectively. The nature of the voluntary reporting 
database implies several limitations such as under-reporting and lack of central quality 
control by expert panel. Since ADR reports of KIDS-KARES database were anonymized, 
additional information could not be assessed. As such, it was impossible to determine if the 
11 single-center patients were included in the KIDS-KAERS. Secondly, a limited number of 
patients agreed to participate in the SPT and BAT. Most patients could find culprit drug after 
multiple OPTs, and then refused an additional SPT or BAT test. Thirdly, the possibility that 
eperisone metabolites causes IgE-mediated reaction could not be verified in this study. If 
eperisone metabolite is a culprit, SPT and BAT using eperisone itself can be negative.
In conclusion, eperisone induces anaphylaxis possibly by inducing non-IgE-mediated 
immediate hypersensitivity. Thus, it should be considered a cause of anaphylaxis in pain 
medications. The OPT under supervision of an allergy specialist appears to be the optimal 
diagnostic modality for eperisone-induced anaphylaxis.
SUPPLEMENTARY MATERIALS
Supplementary Table S1
Baseline characteristics of the patients with ADRs to eperisone in Korea from the KIDS-
KAERS database (n =207)
Click here to view
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Supplementary Table S2
Clinical manifestations of ADRs to eperisone from the KIDS-KAERS database (n = 207)
Click here to view
Supplementary Table S3
Data on eperisone-induced ADR at a single pharmacovigilance center (n = 37)
Click here to view
Supplementary Fig. S1
Allergy test results of the patients with anaphylaxis. (A) Basophil activation test. (B) 
Generalized urticaria and angioedema after open challenge test.
Click here to view
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